Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase
  • Alleles
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • Class I Phosphatidylinositol 3-Kinases / genetics
  • Class I Phosphatidylinositol 3-Kinases / metabolism
  • Gene Expression
  • Gene Frequency
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Molecular Targeted Therapy
  • Prognosis
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism
  • Purines / therapeutic use
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Quinazolinones / therapeutic use
  • Sulfonamides / therapeutic use
  • Tumor Suppressor Protein p53 / deficiency
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Bridged Bicyclo Compounds, Heterocyclic
  • Purines
  • Pyrazoles
  • Pyrimidines
  • Quinazolinones
  • Sulfonamides
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • ibrutinib
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CD protein, human
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • venetoclax
  • idelalisib